Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 9/20 | 0.80 |
| ▸ | HTR2A | P28223 | 5/20 | 0.80 |
| ▸ | HTR2C | P28335 | 5/20 | 0.80 |
| ▸ | HTR2B | P41595 | 5/20 | 0.80 |
| ▸ | HTR1D | P28221 | 4/20 | 0.80 |
| ▸ | HTR1E | P28566 | 4/20 | 0.80 |
| ▸ | HTR6 | P50406 | 4/20 | 0.80 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR5A | P47898 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20546707 | 0.89 | HTR7 (1.00) | HTR7HTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL12340041 | 0.84 | SOS1 (1.00) | HTR7HTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL5644368 | 0.84 | HTR7 (0.80) | HTR7HTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL10818201 | 0.84 | HTR7 (0.79) | HTR7HTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL10817002 | 0.84 | SOS1 (0.68) | HTR7HTR2AHTR2CHTR2BHTR1D | |
| Hydrochloric Acid SCHEMBL30785564 | 0.83 | HTR7 (0.78) | HTR7HTR2AHTR2CHTR2BHTR1D | |
| Hydrochloric Acid SCHEMBL3441395 | 0.83 | SOS1 (0.97) | HTR7HTR2AHTR2CHTR2BHTR1D | |
| Hydrochloric Acid SCHEMBL2258457 | 0.83 | HTR7 (0.77) | HTR7HTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL807194 | 0.83 | SOS1 (0.70) | HTR7HTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL10818194 | 0.82 | SOS1 (0.69) | HTR7HTR2AHTR2CHTR2BHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181142-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS INC (US) | 2020-06-11 | — | — | US | disclosed |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181142-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | HTR7 4347/4885HTR2A 4242/4885HTR2C 4521/4885 |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | HTR7 4347/4885HTR2A 4242/4885HTR2C 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.